

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION NO.3241
TO BE ANSWERED ON THE 7TH AUGUST 2026

PLI Scheme for Bulk Drugs

3241. Shri Radhakrishna:

Shri G Lakshminarayana:

Will the Minister of **Chemicals and Fertilizers** be pleased to state:

- (a) the number of projects approved under the Production Linked Incentive (PLI) Scheme for Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs) and Drug Intermediates, indicating the committed, approved and actual investment made thereunder, State-wise;
- (b) the details of funds allocated/sanctioned/released/utilized and production capacity approved and commissioned under the scheme, State-wise;
- (c) the quantity and value of production achieved by approved units during the last three years, State-wise and year-wise;
- (d) the details of incentives sanctioned and disbursed under the said scheme along with the number of projects that have not commenced commercial production;
- (e) whether any assessment has been made regarding reduction in import dependence for approved APIs and KSMs since commencement of the said scheme, if so, the details thereof indicating the reductions achieved in import dependence for specific APIs identified for import substitution, API-wise; and
- (f) the details of APIs, if any where import dependence has not reduced despite scheme approval?

ANSWER

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS

(SMT. ANUPRIYA PATEL)

(a) to (e): 48 projects have been approved under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI Scheme for Bulk Drugs). The scheme has an approved outlay of ₹6,940 crore out of which ₹87.70 crore has been utilized in disbursement of incentive to approved applicants as of March, 2026. Further, production capacity has been created for 28 APIs/KSMs/DIs. Out of these 10 have not achieved commercial production. As of March 2026, cumulative investment of ₹5,070.45 crore has been achieved against a committed investment of ₹4,329.95 crore. The State-wise details of approved projects, committed investment, actual investment made, production capacity approved, capacity created, quantity and value of production achieved and incentive disbursement are placed at **Annexure-A**.

(f): The list of 41 products approved under PLI scheme for Bulk Drugs is placed at **Annexure-B.**, Out of these, production of following 18 APIs has commenced, thereby reducing import dependency – Penicillin G, Clavulanic Acid, Dexamethasone, Prednisolone, Para Amino Phenol, 1,1 Cyclohexane Diacetic Acid (CDA), Dicyandiamide (DCDA), Atorvastatin, Levofloxacin, Sulfadiazine, Ofloxacin, Norfloxacin, Artesunate, Telmisartan, Lopinavir, Carbamazepine, Oxcarbazepine and Diclofenac Sodium.

Annexure-A

**Annexure referred to in the reply to part (a) to (e) of the Lok Sabha Unstarred Question
No. 3241, to be answered on 7.8.2026**

Name of State	No. of projects approved	Investment(in crore ₹)		Capacity (in MT)		Production Qty.(in MT)			Production value(in crore ₹)			Incentive released (in crore ₹)
		Committed	Actual	Committed	Installed	2023-24	2024-25	2025-26	2023-24	2024-25	2025-26	
Andhra Pradesh	10	1,745.7	2,676	24,390	16,468	224.4	1,207.4	5,498.6	63.2	258.4	865.7	31.91
Gujarat	8	330.9	407.3	14,270	13,959	7,028.7	4,170	5,572.7	209.5	133.1	162.9	11.3
Haryana*	1	81	37	800	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
Himachal Pradesh	2	806.8	502.6	1,100	400	0.01	69.9	172.1	0	115.9	242.6	11.98
Jammu & Kashmir*	1	185	338.65	1,000	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
Karnataka	3	96.9	201.4	37	16.7	0	0	0.9	0	0	3.12	NIL
Madhya Pradesh	2	280	101.8	1,015	15	3.63	4.93	0.32	24.71	33.37	3.2	NIL
Maharashtra	5	308.4	168.8	40,185	19,180	611.9	500.3	1.14	27.51	26.41	0.01	NIL
Punjab	1	137.7	161.1	180	206	91.4	79.6	58.15	119.53	96.9	72.01	27.18
Tamil Nadu	2	31.5	45.6	280	280	3.1	0.0025	5.73	0.8	0.01	1.24	NIL
Telangana	13	326.02	430.2	7,820	7,820	103.1	89.4	108.03	87.4	85.8	101.5	5.23

* Projects in state of Haryana and UT of J&K are under commissioning stage.

Annexure-B

Annexure referred to in the reply to part (f) of the Lok Sabha Unstarred Question No. 3241, to be answered on 7.8.2026

S. No.	Name of KSM/DI/API
Key Fermentation based KSMs / Drug Intermediates	
1	Penicillin G
2	7-ACA
3	Erythromycin Thiocynate (TIOC)
4	Clavulanic Acid
Fermentation based niche KSMs I Drug Intermediates I APIs	
5	Neomycin
6	Gentamycin
7	Betamethasone
8	Dexamethasone
9	Prednisolone
10	Rifampicin
11	Vitamin BI
12	Clindamycin Base
13	Streptomycin
14	Tetracycline
Key Chemical Synthesis based KSMs I Drug Intermediates	
15	1,1 Cyclohexane Diacetic Acid (CDA)
16	2-Methyl-5Nitro-Imidazole (2-MNI)
17	Dicyandiamide (DCDA)
18	Para amino phenol
Other Chemical Synthesis based KSMs I Drug Intermediates / APIs	
19	Meropenem
20	Atorvastatin
21	Olmesartan
22	Valsartan
23	Losartan
24	Levofloxacin
25	Sulfadiazine
26	Ciprofloxacin
27	Ofloxacin
28	Norfloxacin
29	Artesunate
30	Telmisartan
31	Aspirin
32	Diclofenac Sodium
33	Leveti racetam

34	Carbidopa
35	Ritonavir
36	Lopinavir
37	Acyclovir
38	Carbamazepine
39	Oxcarbazepine
40	Vitamin B6
41	Levodopa
